Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.

International Journal of Clinical Practice
Juana Carretero GómezDiabetes, Obesity and Nutrition Spanish Working Group

Abstract

We aimed to determine the efficacy and safety of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists to prevent worsening urinary albumin-to-creatinine ratio as an early biomarker of diabetes kidney disease. A total of 178 patients with type 2 diabetes and obesity received combination treatment with SGLT2i added to GLP1ra (n = 76), GLP1ra added to SGLT2i (n = 50) or GLP1ra plus SGLT2i from start (n = 52), according to investigators´ best clinical judgement. Major outcomes assessed at 26 weeks were changes in urine albumintocreatinine-ratio (UACR), estimated glomerular filtration rate (eGFR), glycated haemoglobin, body weight and systolic blood pressure. All patients (58.6% men, mean age 61.9 ± 10.0 years) completed the study. Baseline HbA1c, weight and eGFR levels were 8.2 ± 0.9%, 109.9 ± 19 kg and 83.3 ± 19.6 mL/min/m2 , respectively. At 26 weeks, we found significant reductions in HbA1c (1.16%), weight (5.17 kg) and systolic blood pressure (8.13 mmHg). The reduction in UACR was 15.14 mg/g (95% CI 8.50-22.4) (-24.6 ± 64.7%), which was greatest in the group of patients with SGLT2i added on to GLP1ra therapy (116.7 mg/g; 95% CI: 54-296.5 mg/g; P < .001. Patients with urinary albu...Continue Reading

References

May 1, 1992·Hypertension·M Epstein, J R Sowers
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Mar 27, 2013·Nature Reviews. Nephrology·Marcus J Moeller, Verena Tenten
Dec 4, 2014·Diabetes Research and Clinical Practice·Hans-Henrik ParvingPeter Rossing
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Feb 7, 2017·Diabetic Medicine : a Journal of the British Diabetic Association·D N KoyeD J Magliano
May 4, 2017·Journal of the American Society of Nephrology : JASN·Joshua J NeumillerKatherine R Tuttle
May 20, 2017·Clinical Journal of the American Society of Nephrology : CJASN·Radica Z AlicicKatherine R Tuttle
Aug 22, 2017·Canadian Journal of Diabetes·Ronald M GoldenbergJordan J Weinstein
Dec 12, 2017·BMJ Global Health·Brendon Lange NeuenVlado Perkovic
Jun 26, 2018·The Lancet. Diabetes & Endocrinology·Vlado PerkovicBruce Neal
Sep 27, 2018·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·José Carlos Arévalo-LoridoJavier Ena Muñoz
Nov 13, 2018·Canadian Journal of Diabetes·Juana Carretero GómezUNKNOWN Diabetes, Obesity, and Nutrition Spanish Working Group
Jan 13, 2019·The Lancet. Diabetes & Endocrinology·Josef CoreshUNKNOWN Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration
Jan 13, 2019·The Lancet. Diabetes & Endocrinology·Hiddo J L HeerspinkUNKNOWN Chronic Kidney Disease Epidemiology Collaboration

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.